$SJM — AVOID 📊 | 6 MONTHS THESIS

$SJM — AVOID 📊 | 6 MONTHS THESIS 🧭 Conviction: MED 🎯 FQ4 FY2027 (ends Apr) | reported Jun 09 | Rev $2.3B | EPS $3.63 vs $2.64 🟢 | Margin -23.4% 💡 Consensus expects ongoing deterioration; the 37% EPS beat was on an adjusted basis, but GAAP losses persist. The market is likely right to discount the beat given the magnitude of one-off charges—the gap between adjusted and GAAP earnings is a red flag, not an opportunity. 🏢 Business Quality: 3/10 📊 Valuation: Cheap on trailing adjusted P/E (8.0x vs. consumer staples median ~15x) but rich on GAAP (negative net income). 🔮 Catalyst: Next quarterly earnings release ⚖️ Avoid: The adjusted earnings beat masks GAAP losses and high debt; low quant ranks and negative margins suggest value trap—wait for clear margin recovery.

🧭 Conviction: MED